The identification of the ER as a therapeutic target led to a paradigm shift in the treatment of breast cancer and the development of a number of different classes of hormonal therapy, in particular, selective SERM, SERD, and AI [40]. This evidence concerns the gene ESR1 and breast carcinoma.